Nektar Therapeutics reported financial results for the quarter ended June 30, 2026. Revenue was $10.1 million compared to $11.2 million in the prior year period. The company reported a net loss of $40.6 million, or $1.23 per share, versus a net loss of $41.6 million, or $2.95 per share, in the same quarter last year. Cash and investments increased to $1,023.4 million from $245.8 million at year-end 2025, primarily due to a public offering completed in April 2026 that raised $373.8 million in gross proceeds. The company initiated Phase 3 trials for its lead drug rezpegaldesleukin in atopic dermatitis and plans to begin studies in alopecia areata in early 2027. Nektar Therapeutics is a clinical-stage biotechnology company focused on developing immunology therapies.